Zogenix to Present at Two Investor Conferences in April
EMERYVILLE, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that members of management will participate on panels and host investor meetings at two conferences in April: Stifel First Annual CNS Day and William Blair 3rd Annual Late-Stage Therapeutics Conference.
|
Stifel First Annual CNS Day | |
| Date: | Monday, April 1, 2019 |
| Location: | The Four Seasons Hotel, Boston |
| Panel: | Future of Epilepsy Treatment |
| Participant: | Stephen J. Farr, President and Chief Executive Officer |
| Time: | 3:35 PM Eastern Time / 12:35 PM Pacific Time |
| William Blair 3rd Annual Late-Stage Therapeutics Conference | |
| Date: | Thursday, April 4, 2019 |
| Location: | Omni Berkshire Place, New York |
| Panel: | New Therapies for Epileptic Disorders |
| Participant: | Gail Farfel, Ph.D., Executive Vice President & Chief Development Officer |
| Time: | 8:00 AM Eastern Time / 5:00 AM Pacific Time |
About Zogenix
Zogenix is a global pharmaceutical company committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases. The company’s lead candidate, FINTEPLA® (ZX008, fenfluramine) has been accepted for review by the European Medicines Agency; is awaiting an acceptance decision by the U.S. Food & Drug Administration; and is in development in Japan. For more information, visit www.zogenix.com.
CONTACT:
Zogenix
Melinda Baker
Senior Director, Corporate Communications
media@zogenix.com
Media
Rachel Lipsitz
Public Relations, Syneos Health
+1 (858) 449 9575 | rachel.lipsitz@syneoshealth.com
Investors
Andrew McDonald
Founding Partner, LifeSci Advisors LLC
+1 (646) 597-6987 | Andrew@lifesciadvisors.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
